{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.05","upperLimit":"0.85","value":"0.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Extramedullary response, defined as a response by extramedullary plasmacytoma or plasma cell count parameters. The extramedullary response rate will be estimated by the number of responders(patients that achieved a partial or complete response) divided by the number of evaluable patients. Exact binomial confidence intervals will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Dexamethasone: Given PO Ixazomib Citrate: Given PO Laboratory Biomarker Analysis: Correlative studies Pomalidomide: Given PO","id":"OG000","title":"Treatment (Ixazomib Citrate, Pomalidomide, Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"All patients with extramedullary disease that were evaluated for response.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Extramedullary Response Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}